Protocol Ledger

NCT04456387 · Phase III · COMPLETED

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Interventional Phase III clinical trial protocol NCT04456387 sponsored by Zhengzhou Gensciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-15 Enrollment: 119 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04456387
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)119 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04456387
Protocol FieldVerified Registry Value
NCT IdentifierNCT04456387
Consolidated Lead SponsorZhengzhou Gensciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment119 participants (ACTUAL)
Registered Start Date2020-10-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI